Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ICG-001 |
Synonyms | |
Therapy Description |
ICG-001 disrupts the interaction of CTNNB1 and c-AMP response element-binding protein, thereby preventing downstream CTNNB1 signaling to promote apoptosis (PMID: 15314234, PMID: 29332125, PMID: 32642722). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ICG-001 | ICG001|ICG 001 | CTNNB1 Inhibitor 27 | ICG-001 disrupts the interaction of CTNNB1 and c-AMP response element-binding protein, thereby preventing downstream CTNNB1 signaling to promote apoptosis (PMID: 15314234, PMID: 29332125, PMID: 32642722). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
APC inact mut | colon cancer | sensitive | ICG-001 | Preclinical | Actionable | In a preclinical study, ICG-001 decreased cell proliferation in colon cancer cell lines and in mouse models carrying APC inactivating mutations (PMID: 15314234). | 15314234 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|